Literature DB >> 28361379

Bevacizumab for treatment of choroidal neovascularization secondary to candida chorioretinitis.

Georgios Makragiannis1, Kaveh Vahdani1, Ester Carreño2, Richard W J Lee1,3,4, Andrew D Dick1,3,4, Adam H Ross1.   

Abstract

PURPOSE: To report a case of juxtafoveal choroidal neovascularization in a patient with candida chorioretinitis successfully treated with intravitreal bevacizumab.
METHODS: Case report.
RESULTS: A 45-year-old woman previously treated for candida chorioretinitis was presented with reduced vision in the left eye. The patient was investigated with ophthalmoscopy, fluorescein angiography, and optical coherence tomography (OCT). Following initial treatment, fundus examination, fluorescein angiography, and OCT of the right eye revealed a secondary juxtafoveal classic choroidal neovascularization. Following a single intravitreal injection of bevacizumab, the patient had excellent visual recovery, with absence of subretinal or intraretinal fluid in the OCT.
CONCLUSIONS: Bevacizumab was effective in treatment of choroidal neovascularization associated with candida chorioretinitis.

Entities:  

Keywords:  Bevacizumab; Candida; Chorioretinitis; Choroidal neovascular membrane

Mesh:

Substances:

Year:  2017        PMID: 28361379     DOI: 10.1007/s10792-017-0502-x

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  17 in total

1.  Intravitreal Ranibizumab in the treatment of choroidal neovascularisation secondary to ocular toxocariasis in a 13-year-old boy.

Authors:  D A M Lyall; B M Hutchison; A Gaskell; M Varikkara
Journal:  Eye (Lond)       Date:  2010-10-08       Impact factor: 3.775

2.  Photodynamic therapy outcomes in a case of macular choroidal neovascularization secondary to Candida endophthalmitis.

Authors:  M Tedeschi; M Varano; D Schiano Lomoriello; C Scassa; V Parisi
Journal:  Eur J Ophthalmol       Date:  2007 Jan-Feb       Impact factor: 2.597

3.  Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to endogenous endophthalmitis.

Authors:  Shwu-Jiuan Sheu
Journal:  Kaohsiung J Med Sci       Date:  2009-11       Impact factor: 2.744

4.  Intravitreal bevacizumab for treatment of choroidal neovascularization secondary to toxoplasmic retinochoroiditis: a case series.

Authors:  Farzan Kianersi; Afsaneh Naderi Beni; Zahra Naderi Beni; Heshmatollah Ghanbari
Journal:  Semin Ophthalmol       Date:  2013-10-31       Impact factor: 1.975

5.  Ocular manifestations of candidemia.

Authors:  Astrid M L Oude Lashof; Aniki Rothova; Jack D Sobel; Markus Ruhnke; Peter G Pappas; Claudio Viscoli; Haran T Schlamm; Iwona T Oborska; John H Rex; Bart Jan Kullberg
Journal:  Clin Infect Dis       Date:  2011-08-01       Impact factor: 9.079

6.  Visual and anatomical outcome following submacular surgery for choroidal neovascularization secondary to Candida endophthalmitis.

Authors:  Franco M Recchia; Guarav K Shah; Ralph C Eagle; Arunan Sivalingam; David H Fischer
Journal:  Retina       Date:  2002-06       Impact factor: 4.256

7.  Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1994-04

8.  Pathological findings of multifocal choroiditis with panuveitis and punctate inner choroidopathy.

Authors:  Hiroyuki Shimada; Mitsuko Yuzawa; Tokihito Hirose; Hiroyuki Nakashizuka; Takayuki Hattori; Yoko Kazato
Journal:  Jpn J Ophthalmol       Date:  2008-09-05       Impact factor: 2.447

9.  Phase IIb clinical trial of ranibizumab for the treatment of uveitic and idiopathic choroidal neovascular membranes.

Authors:  Ester Carreño; Tanya Moutray; Konstantinos Fotis; Richard W J Lee; Andrew D Dick; Adam H Ross; Clare Bailey
Journal:  Br J Ophthalmol       Date:  2015-12-16       Impact factor: 4.638

10.  Toxocara polymerase chain reaction on ocular fluids in bilateral granulomatous chorioretinitis.

Authors:  Jenny Xue Tian; Stephen O'Hagan
Journal:  Int Med Case Rep J       Date:  2015-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.